Last reviewed · How we verify
Gecacitinib Hydrochloride Tablets
At a glance
| Generic name | Gecacitinib Hydrochloride Tablets |
|---|---|
| Also known as | Gecacitinib |
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV (NA)
- Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma (PHASE1, PHASE2)
- Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy (PHASE2)
- Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: